Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al

Saved in:
Bibliographic Details
Published inESC Heart Failure Vol. 5; no. 6; pp. 1069 - 1071
Main Authors Ramires, Felix J.A., Martinez, Felipe, Gómez, Efraín A., Demacq, Caroline, Gimpelewicz, Claudio R., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Packer, Milton, McMurray, John J.V.
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.12.2018
John Wiley and Sons Inc
Subjects
Cardiomyopathy
Chagas Cardiomyopathy
Chagas Disease
Clinical Medicine
Correspondence
Heart
Heart Failure
Humans
Ivabradine
Klinisk medicin
Letter to the Editor
Morbidity
Mortality
Brazil
New York
United States > US
Europe
Latin America
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.12355